A fast, sensitive, and high throughput method for the determination of nintedanib in mouse plasma by UPLC-MS/MS

被引:9
作者
Xu, Dan [1 ]
Zhang, Yang [1 ]
Dai, Juji [2 ]
Bai, Yongyu [2 ]
Xiao, Yuwu [2 ]
Zhou, Meng-tao [2 ]
机构
[1] Wenzhou Med Univ, Hosp Eye, Wenzhou 325000, Peoples R China
[2] Wenzhou Med Univ, Affiliated Hosp 1, Wenzhou 325000, Peoples R China
基金
中国国家自然科学基金;
关键词
IDIOPATHIC PULMONARY-FIBROSIS; TYROSINE KINASE INHIBITOR; BIBF; 1120; OPEN-LABEL; ANGIOKINASE INHIBITOR; SAFETY; EFFICACY; CANCER;
D O I
10.1039/c5ay01207d
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
A sensitive and rapid ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) method was developed to determine nintedanib in mice plasma using diazepam as the internal standard (IS). Sample preparation was accomplished through a protein precipitation procedure using acetonitrile. The analyte and IS were separated on an ACQUITY UPLC BEH C18 column (2.1 mm x 50 mm, 1.7 mu m) with the mobile phase of acetonitrile and 0.1% formic acid in water with gradient elution at a flow rate of 0.40 mL min(-1). The detection was performed on a triple quadrupole tandem mass spectrometer equipped with positive-ion electrospray ionization (ESI) by multiple reaction monitoring (MRM) of the transitions at m/z 540.3 -> 113.0 for nintedanib and m/z 285.2 -> 193.1 for IS. The linearity of this method was found to be within the concentration range of 0.1-500 ng mL(-1) with a lower limit of quantification of 0.1 ng mL(-1). Only 3.0 min was needed for an analytical run. The method described herein was superior to previous methods and was successfully applied to the pharmacokinetic study of nintedanib in mice after oral administration.
引用
收藏
页码:6561 / 6565
页数:5
相关论文
共 19 条
[1]  
[Anonymous], 2018, Bioanalytical method validation guidance for industry
[2]   Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis [J].
Chaudhary, N. I. ;
Roth, G. J. ;
Hilberg, F. ;
Mueller-Ouernheim, J. ;
Prasse, A. ;
Zissel, G. ;
Schnapp, A. ;
Park, J. E. .
EUROPEAN RESPIRATORY JOURNAL, 2007, 29 (05) :976-985
[3]  
Coward William R, 2010, Ther Adv Respir Dis, V4, P367, DOI 10.1177/1753465810379801
[4]   Evaluation of ultra performance liquid chromatography -: Part I.: Possibilities and limitations [J].
de Villiers, Andre ;
Lestremau, Francois ;
Szucs, Roman ;
Gelebart, Sylvie ;
David, Frank ;
Sandra, Pat .
JOURNAL OF CHROMATOGRAPHY A, 2006, 1127 (1-2) :60-69
[5]   Nintedanib: A Novel Therapeutic Approach for Idiopathic Pulmonary Fibrosis [J].
Dimitroulis, Ioannis A. .
RESPIRATORY CARE, 2014, 59 (09) :1450-1455
[6]   Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study [J].
Eisen, Tim ;
Shparyk, Yaroslav ;
Macleod, Nicholas ;
Jones, Robert ;
Wallenstein, Gudrun ;
Temple, Graham ;
Khder, Yasser ;
Dallinger, Claudia ;
Studeny, Matus ;
Loembe, Arsene-Bienvenu ;
Bondarenko, Igor .
INVESTIGATIONAL NEW DRUGS, 2013, 31 (05) :1283-1293
[7]   Phase I Open-Label Study of Continuous Treatment with BIBF 1120, a Triple Angiokinase Inhibitor, and Pemetrexed in Pretreated Non-Small Cell Lung Cancer Patients [J].
Ellis, Peter M. ;
Kaiser, Rolf ;
Zhao, Yihua ;
Stopfer, Peter ;
Gyorffy, Steve ;
Hanna, Nasser .
CLINICAL CANCER RESEARCH, 2010, 16 (10) :2881-2889
[8]   A New Hope for Idiopathic Pulmonary Fibrosis [J].
Hunninghake, Gary M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (22) :2142-2143
[9]   Treatments for Idiopathic Pulmonary Fibrosis [J].
Ohkubo, Hirotsugu ;
Takeda, Norihisa ;
Niimi, Akio .
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (08) :782-782
[10]  
Kropff M, 2009, ANTICANCER RES, V29, P4233